BIOPOLE, EPALINGES, V8
Retention Awards Approved for Executive Officers at ADC Therapeutics
5 Topline Results Presentation JUNE 3, 2026
Shareholder Approval of Annual Financial Statements at ADC Therapeutics
Reports First Quarter 2026 Financial Results and Provides Operational Updates
Financial Results, Press Release
Annual Report to Security Holders
ADC Therapeutics Enters Amendment to Material Definitive Agreement
Corporate Presentation January 2026
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence